ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Association of Alzheimer's disease concerns with amyloid burden and lifestyle behaviors in cognitively unimpaired older adults.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02008357 (Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Who cites it
2 citing papers in PubMed.
- Sleep-Dependent Clearance of Brain Metabolites via the Glymphatic System: Implications for Alzheimer's Pathophysiology.Brain and behavior · 2026Review
- Association of Alzheimer's disease concerns with amyloid burden and lifestyle behaviors in cognitively unimpaired older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionThe extent to which Alzheimer's disease (AD) concerns relate to pathological changes in cognitively unimpaired populations is unclear.
methodsWe analyzed screening data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) study to determine if AD concerns are associated with amyloid burden in cognitively unimpaired older adults, and how they relate to lifestyle. AD concerns were measured using the six-item Concerns about Alzheimer's Disease Questionnaire. Regression estimated the association of AD concerns with amyloid burden, adjusting for covariates.
resultsOf 4460 individuals, AD concerns were elevated in women, people with a dementia family history, apolipoprotein E (APOE) ε4 carriers, and individuals who did not meet walking or sleep guidelines. AD concerns were associated with higher amyloid burden (β [95% CI] = 0.002 [0.001-0.003], p = 0.007), with stronger effects in APOE ε4 carriers. DISCUSSION: AD concerns were associated with a core diagnostic AD biomarker. Assessing AD concerns could inform future recruitment strategies. Clinical Registration Trial:: ClinicalTrials.gov: ID NCT02008357. HIGHLIGHTS: Alzheimer's disease (AD) concerns were associated with higher amyloid burden. AD concerns were associated with higher depressive symptoms in apolipoprotein E (APOE) ε4 carriers. Concerns were associated with a lower likelihood of meeting daily walking guidelines. Associations were stronger in APOE ε4 carriers compared to non-carriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.